D
David Brosh
Researcher at Rabin Medical Center
Publications - 45
Citations - 3068
David Brosh is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 23, co-authored 45 publications receiving 2980 citations. Previous affiliations of David Brosh include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
Donald S. Silverberg,Dov Wexler,Miriam Blum,Gad Keren,David S. Sheps,Eyal Leibovitch,David Brosh,Shlomo Laniado,Doron Schwartz,Tatyana Yachnin,Itzhak Shapira,Dov Gavish,Ron Baruch,Bella Koifman,Carl P Kaplan,Shoshana Steinbruch,Adrian Iaina +16 more
TL;DR: Anemia is very common in CHF and its successful treatment is associated with a significant improvement in cardiac function, functional class, renal function and in a marked fall in the need for diuretics and hospitalization.
Journal ArticleDOI
Main Risk Factors for Nephropathy in Type 2 Diabetes Mellitus Are Plasma Cholesterol Levels, Mean Blood Pressure, and Hyperglycemia
TL;DR: The combination of blood pressure values in the high-normal range with moderately elevated levels of total cholesterol and hemoglobin A1c defines a high-risk group for the progression to diabetic nephropathy and for clinical events related to arteriosclerotic cardiovascular disease.
Journal Article
Use of Enalapril To Attenuate Decline in Renal Function in Normotensive, Normoalbuminuric Patients with Type 2 Diabetes Mellitus
TL;DR: A randomized, double-blind, placebo-controlled trial of the effect of ACE inhibition on the course of nephropathy in 156 patients with type 2 diabetes, who had normal blood pressure and normal urinary albumin excretion at baseline and who attended one of eight clinics in the greater Tel-Aviv area.
Journal ArticleDOI
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.
TL;DR: In this paper, the authors evaluated the effect of prolonged ACE inhibition on renal function and albuminuria in patients with type 2 diabetes and found that enalapril treatment resulted in an absolute risk reduction of 12.5% (95% CI, 2% to 23%; P = 0.042) for development of microalbuminuria.
Journal ArticleDOI
Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality.
David Brosh,Abid Assali,Aviv Mager,Avital Porter,David Hasdai,Igal Teplitsky,Eldad Rechavia,Shmuel Fuchs,Alexander Battler,Ran Kornowski +9 more
TL;DR: The association of no-reflow with longer ischemic time and worse initial TIMI flow may indicate the presence of highly organized thrombus burden with higher propensity for distal embolization.